Current lead clinical programs are evaluating the locoregional delivery of CAR T cells targeting the glioma TAA interleukin-13 receptor (IL13R)α2, a high-affinity IL13 receptor, and has open trials for IL13Rα2-CAR as a single agent therapy for recurrent high-grade glioma [9, 12] (NCT02208362) and other primary brain tumors (NCT04661384) [13] in combination with checkpoint inhibition [14] (NCT04003649; or with added lymphodepletion (NCT04510051). Here, IL13RA2 is linked to brain neoplasm.